Pegasys
Pegasys is a pharmaceutical drug with 37 clinical trials. Historical success rate of 91.4%.
Success Metrics
Based on 32 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
13
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
91.4%
32 of 35 finished
8.6%
3 ended early
0
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
Clinical Trials (37)
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients
Study of SCY-635, Pegasys and Copegus in Hepatitis C
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37